SureTrader
Interactive Brokers Advertisement
Home > Boards > Canadian > Biotechs >

Breathtec Biomedical Inc. (BTHCF)

BTHCF RSS Feed
Add BTHCF Price Alert      Hide Sticky   Hide Intro
Moderator: shell3, AMG, DiamondInTheRough, smoki, hoyowasobo
Search This Board: 
Last Post: 11/22/2017 11:59:17 PM - Followers: 68 - Board type: Free - Posts Today: 0

 
 


 
September 5th 2017 


Issued and outstanding common shares 54,752,024 

Warrants outstanding 26,029,676 

Stock options outstanding. 3,495,000 


http://thecse.com/sites/default/files/Breathtec_-_CSE_Form_7_-_Monthly_Progress_Report_for_August_2017_-_Completed.pdf
 

http://breathtecbiomedical.com
 

Breathtec Biomedical, Inc. (“Breathtec”) was formed to propel innovative research in the area of breath analysis as a medical screening tool. Our efforts are aimed at leading the development of commercially viable methods for the early screening of diseases such as lung & breast cancers, neurodegenerative diseases (eg: Alzheimer’s / Parkinson’s), tuberculosis, diabetes, liver disease and more.

Our primary avenue of investigation is focused on innovation and advances in the field of specialized mass spectrometry.

The principal market opportunity arises from the potential of low-cost, non-intrusive diagnostic screening in general medical practice which could lead to notable advances in early detection of major cancers and other life-altering diseases.

Regular screening using a simple breath test, could lead to significant advancements in remedial treatment protocols targeting major improvements in survivability and life


 

High-Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS)

Function: Compounds (Ions) are Separated by Mobility

  • Function of the size, shape, charge
    Direct, real-time separation
    Continuous sample introduction

An Ion filter – only molecules of interest are allowed to be detected
[ima][/img]
https://m.youtube.com/watch?v=tBViWFNtZUk

FAIMS Technical Overview

Breathtec Biomedical aims to assist the development of novel instrumentation and methodologies for high-field asymmetric waveform ion mobility spectrometry(FAIMS). FAIMS can be performed on a standalone device, or, more prominently, coupled to a mass spectrometer (MS). FAIMS is a separation technique which allows continuous sample introduction, enabling direct, real-time analysis.

FAIMS (or differential mobility spectrometry, DMS) involves separation based on the inherent differences in an ion’s mobility in high and low electric fields, and can be performed at atmospheric pressure and room temperature

Corporate Presentation
http://3jxjjl3cm6sh2pusp2ofxrx3.wpengine.netdna-cdn.com/wp-content/uploads/2015/10/BreathTec-Corporate-Presentation.pdf

Company filings
http://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00037722



Leadership

Chief Executive Officer

Undecided 


 

Alfred Wong

Vice President, Corporate Development & Communications
2017 - Current 
Breathtec Biomedical, Inc. engages in the provision of medical diagnostic and health-related technology. It involves in the development of commercially viable methods such as of breath analysis screening technologies for the early screening of diseases such as lung, breast cancers, neurodegenerative diseases, tuberculosis, diabetes, liver diseases, and others. The company was founded on January 22, 2015 and is headquartered in Vancouver. Canada.

 


raj

Raj Attariwala, MD, PhD., Lead Engineer

Dr. Attariwala is a dual board certified Radiologist and Nuclear Medicine physician certified in both Canada and the United States. He received his formal medical training at University of British Columbia with periods of specialized medical training at Memorial Sloan Kettering Cancer Centre (New York), UCLA and USC. He holds a doctorate in Biomedical Engineering from Northwestern University (Evanston, IL).

Dr. Attariwala is a practicing physician in British Columbia and owner of AIM medical imaging. He has pioneered advances in the field of whole body medical imaging and authored numerous publications and presented at international medical conferences on whole body imaging and cancer detection.

Dr. Attariwala has extensively investigated breath testing applications and efficacy in a related role at Cannabix Technologies Inc. where he developed a breath testing system for drug impairment.


yost

Richard A. Yost Ph.D., Scientific Advisor

Dr. Yost, Col. Allen R. & Margaret G. Crow Professor and Head of Analytical Chemistry at the University of Florida received his B.S. degree in Chemistry from the University of Arizona in 1974. In 1975 he pursued an NSF graduate fellowship at Michigan State University focusing on electronics and computerized instrumentation. He received his Ph.D. in 1979 and assumed the position of Assistant Professor at the University of Florida and went on to become head of the Analytical Chemistry Division.

Dr. Yost’s research has involved over 100 graduate students funded by over $40 million in research grants, and has published over 160 papers and 16 patents. Over $30 billion worth of instruments have been sold based on these patents.

He serves as a member of the Florida Board of Governors (Regents) and as the Chair of the Advisory Council of Faculty Senates of Florida. He is past Chair of the UF Faculty Senate and served on the UF Board of Trustees. He served as Treasurer and Secretary of the American Society for Mass Spectrometry, and on the editorial boards of The Journal of the American Society for Mass Spectrometry and The International Journal of Mass Spectrometry.


 


michael

Michael T. Costanzo, Ph.D., Chief Technical Officer

Dr. Costanzo enjoys a passion for science that has directed his career path firmly into the field of analytical chemistry. Over the past five years he has investigated a variety of advanced experimental methodologies and instrumentation with the Yost Research Group at the University of Florida. During this period he utilized UV spectroscopy to help in standardizing procedures for manufacturing respiratory medications, employed novel ion mobility spectrometric techniques and devices to analyze exhaled breath, and performed multiple metabolomics studies of melanoma. Through his efforts, he acquired a vast knowledge of analytical techniques and methodologies and an immense desire for scientific progress.

Previously, Costanzo obtained his Bachelor of Science in chemistry at the State University of New York (Buffalo). During this period he conducted research under Dr. Troy Wood utilizing mass spectrometry to examine products of enzymatic protein digestion in the interest of studying metabolic markers of autism in children. Upon graduation in 2010 he moved to the University of Florida for Ph.D. studies and as a result of his efforts has recently joined with Breathtec Biomedical to propel his own bioanalytical research through the development of revolutionary clinical devices utilizing his background in ion mobility, mass spectrometry, and exhaled breath analysis.

 


 

BREATHTEC BIOMEDICAL INC.
Suite 890, 789 West Pender Street
Vancouver, British Columbia, Canada V6C 1H2 

 

Breathtec Biomedical Provides Corporate Overview

 

-- Company offers update of events and outlook for near term opportunity

 

VANCOUVER, BRITISH COLUMBIA – October 17, 2016 – Breathtec BioMedical, Inc(CSE: BTH.CN) (CNSX: BTH) (CSE: BTH) (XFRA: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases wishes to address recent corporate events and to provide an update regarding its immediate outlook and future plans.

 

In response to recent volatility in its share price, the Company notesthat fluctuations are an example of development stage market volatility which in Management’s opinion should be viewed in the context of the Company’s underlying financial health and strength of its product portfolio. Breathtec maintains a healthy working capital position of $1.3M. Additionally, management of the Company have voluntarily escrowed a significant number of shares with no insider sales having occurred or contemplatedw.

 

Breathtec’s technology portfolio continues to move ahead with all licensing and development agreements in-place and a number of ongoing achievements and development phases underway. A brief summary of recent and ongoing activities is summarized below. 

 

FAIMS Technology:

Breathtec continues to progress its flagship FAIMS technology with the recent completion of a V2 prototype breathalyzer design. The latest design has significant advances over the previous prototype including larger dynamic range and improved efficiency in the square waveform generator, greater sensitivity achievable by the detector, improvements in the design, implementation of the novel ionization source, and is overall more than 10X smaller than the V1 prototype.The current design is well under development and includes features to allow for the addition of an onboard processor, touch screen and rechargeable battery in a handheld device configuration.

 

 

Regulatory Pathway:

Management has engaged regulatory consultants with extensiveexperience in medical device and in vitro diagnostics strategies to evaluate potential regulatory options to propel the FAIMS technology platforms to market. The Company has furtherengaged experienced product development consultants to initiate the design controls, and quality systems processes to meet regulatory approval and to lead the establishment of product manufacturing protocols as a precursor to commercialization.

 

Professional Collaboration:

Dr. Michael Costanzo, Breathtec’s CTO recently gave a well-received presentation Developing a Point-of-Care Device for Breath Analysis Utilizing FAIMS and FAIMS/MS,” to a prestigious group of leading experts in the field of breath analysis in Zurich, Switzerland. At the event, Dr. Costanzo affirmedBreathtec anticipates completion of a prototype of the FAIMS device in Q4 of 2016 and will work alongside our partner to advance the technology towards the clinic.” Dr. Costanzo’s presentation can be found here: http://breathtecbiomedical.com/news/presentations/.

 

Company CEO at the time, Guy LaTorre comments, “We earnestly appreciate the continued interest and support of all our stakeholders, partners, affiliates and shareholders alike. As such, I wanted to take this opportunity to recap our continued technical achievements as we continue to be motivated daily with overwhelmingly positive feedback as regards the need for a Point-of-Care device such as ours as a means to save countless healthcare dollars and untold numbers of lives in the foreseeable future. These factors compel us to move ahead as quickly as possible with this exciting endeavor and we sincerely thank our supporters for the means to do so.”

 

ON BEHALF OF THE BOARD

 

 

For further information, please contact:
Alfred Wong

President & Director

Breathtec BioMedical, Inc





 


 

 

 

SureTrader
Interactive Brokers Advertisement
BTHCF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#2063  Sticky Note Commercial Adoption of Ion Mobility Technology Drives Multi-Omics Application shell3 07/23/17 11:38:00 AM
#2756   To All Family & Friends & Faithful & AMG 11/22/17 06:15:23 PM
#2755   Thanks Shell also to you and yours and TommyTuna 11/22/17 01:54:10 PM
#2754   Happy Thanksgiving to all on the BTHCF Board shell3 11/22/17 12:47:52 PM
#2753   You all will probably need a lot of AMG 11/21/17 07:27:57 PM
#2752   Maybe- we have another week for excitement? After Carthnel 11/21/17 02:08:30 PM
#2750   BTHCF buy 0.125 stocktrademan 11/21/17 12:10:00 AM
#2749   oops. /////AMG AMG 11/20/17 11:52:37 PM
#2748   hoping to get more shares before we set smoki 11/20/17 07:59:04 PM
#2747   Thought I removed a post ...have to wait smoki 11/20/17 07:54:44 PM
#2746   I feel something is on the way.....) Carthnel 11/20/17 04:27:33 PM
#2745   BTH trading surprisingly decent today so far. EddardStock 11/20/17 10:23:02 AM
#2743   I'm a little happier that I could get Mcfish 11/18/17 04:31:05 AM
#2740   The Encore: AMG 11/17/17 03:32:28 PM
#2739   Down another 10 percent. Shame. Sorry to those medchem 11/17/17 02:53:33 PM
#2738   I can only imagine it would hurt to medchem 11/17/17 02:52:35 PM
#2737   Im only talking about those holding shares. They medchem 11/17/17 02:50:44 PM
#2736   My last post for the day. AMG 11/17/17 12:10:41 PM
#2735   The transparent flip flopping is just amazing. AMG 11/17/17 11:26:21 AM
#2734   Thats actually not true. They share technology but medchem 11/17/17 11:00:00 AM
#2733   Lol i feel bad for those who didnt medchem 11/17/17 10:56:03 AM
#2732   agreed. its a patience game before boom here. hoyowasobo 11/17/17 05:05:48 AM
#2730   looks like you sold and want it to hoyowasobo 11/17/17 04:58:01 AM
#2729   Can you please clarify what company you are AMG 11/17/17 12:16:36 AM
#2728   Blo spent a long time on climate care. iluv blozf 11/16/17 11:06:24 PM
#2727   Agreed. AMG 11/16/17 08:22:40 PM
#2724   If blo device is 95% complete Bth device ILuvblo2 11/16/17 05:07:21 PM
#2723   No CEO, no leadership, no clear path, and medchem 11/16/17 04:28:39 PM
#2722   And with that, allow me to pile on. spliffythecat 11/16/17 03:27:57 PM
#2721   Awww screw it. It's a sad commentary for AMG 11/16/17 01:15:05 PM
#2720   As investors become more aware of the relationship westin Texas 11/16/17 01:14:53 PM
#2719   I sure hope so..if it does I may RolandDoe 11/16/17 12:47:34 PM
#2718   Looks like it is heading back to 8 medchem 11/16/17 12:03:38 PM
#2717   just breath.... and hold no worries it will smoki 11/16/17 11:09:58 AM
#2716   Spoke too soon. Cashed out my double DiamondInTheRough 11/16/17 11:07:06 AM
#2715   Resilient this morning while sister cools down this DiamondInTheRough 11/16/17 10:17:35 AM
#2714   Scottrade US bid 0.156 ask 0.170 DiamondInTheRough 11/16/17 09:29:37 AM
#2713   Schwab on the Ask 17+ smoki 11/16/17 09:26:12 AM
#2712   This one belongs in Every stock holder's Portfolio smoki 11/16/17 09:12:56 AM
#2711   They have the same technology as cAnnabix. They medchem 11/16/17 09:02:14 AM
#2710   TD, BMO, RBC were purchasing yesterday stockmyles 11/16/17 07:40:46 AM
#2709   This will explode again today !! In at .102 stockmyles 11/16/17 07:38:16 AM
#2708   That's Smmmokin Good News. AMG 11/16/17 12:57:36 AM
#2707   Finally BTHCF #16 Breakout Boards and BLOZF #6 shell3 11/16/17 12:20:00 AM
#2706   Amg.. I got both Boards Covered ;)... drop smoki 11/16/17 12:11:39 AM
#2705   Cannabis Investors Are BREATHING Easier As $BLOZF & BugStocks_com 11/15/17 11:36:43 PM
#2704   Thanks again Shell...from the BLO Board. However...DiamondInTheRough is AMG 11/15/17 11:14:07 PM
#2703   The company made no mentions of whether they DiamondInTheRough 11/15/17 04:50:53 PM
#2702   Again glad your Aboard AMG shell3 11/15/17 04:48:37 PM
#2701   I hope to continue to see this run, medchem 11/15/17 04:23:46 PM
#2700   Straight Up ... Firing on All Cylinder's like smoki 11/15/17 04:19:25 PM
PostSubject